Blend Therapeutics Secures $21 Million Financing and Unveils Novel Pentarin Platform for Cancer Therapeutics
![](/46/pdcnewsitem/03/40/40/1qBSXhjVwEBg5mB.png)
Blend Therapeutics has secured $21 million in new funding. The new financing includes additional equity investment from a new investor and all of Blend’s existing venture investors in an expansion of the Series B round, as well as debt financing from an institutional investment firm.
The proceeds of the financing will enable Blend to fully exploit its proprietary Pentarin platform, unveiled, which creates novel, miniaturized biologic drug conjugates encapsulated in nanoparticles, representing a new class of cancer therapeutics. Including the $21 million announced today, Blend has obtained a total of $39.8 million in funding to date. Blend is backed by top-tier venture investors, including New Enterprise Associates, Flagship Ventures, NanoDimension and Eminent Venture Capital.
Blend has also secured a technology licence from a private biotechnology company for novel bi-podal biologic targeting ligands that is an exclusive license in the field of oncology. The in-licensing of this ligand technology is a strategic asset for Blend to develop a robust pipeline of Pentarins. Targeting ligands are one of the core components of Pentarins and Blend’s platform enables the conjugation of the targeting ligand to a therapeutic payload with a chemical linker to create miniaturized biologic drug conjugates (mBDCs), and encapsulates the mBDCs in proprietary nanoparticles to create Pentarins. Together, the components of the Pentarins have distinct yet synergistic anticancer capabilities: the nanoparticle enables high therapeutic concentration at the tumour site; the small size of mBDCs allows for effective penetration and distribution deep into the tumour tissue; the ligand’s targeting ability allows for specific binding to tumour cells; and the cell-killing payload is released inside the cancer cells.
“We are excited to unveil our Pentarin platform as a product engine that creates a new class of cancer therapeutics, and an exceptional opportunity to create value for patients as well as our investors. We look forward to conducting IND-enabling studies to advance our lead Pentarin drug program BTP-277 and completing IND enabling studies of our novel, personalized cisplatin, BTP-114, from our longstanding R&D in platinum drugs” said Richard Wooster, President of R&D of Blend. “Pentarins are an entirely new class of biologic drug conjugates specifically designed for solid tumours, and represent a significant advance in the field since the first development of antibody drug conjugates 35 years ago. We have created Pentarins to have a unique structure, miniaturization and nanoparticle encapsulation that enable the selective targeting of cancer cells and unprecedented penetration deep into tumour tissue, with the aim to improve the treatment of solid tumour cancers for patients.”
In the advancement of Blend’s pipeline of novel drug programmes, the proceeds from the financing will be used to further develop the company’s lead programme, BTP-114, through studies to enable filing of an investigational new drug (IND) application with the FDA. Based on Blend’s historical R&D in novel platinum drug discovery and distinct from the Pentarin platform, BTP-114 is a novel, personalized cisplatin prodrug with novel chemistry designed to preferentially accumulate platinum at the tumour site, deliver a concentrated therapeutic effect and target specific cancers. The funding will also enable Blend to advance its first Pentarin drug candidate, BTP-277, to IND enabling studies as well as exploring other internal Pentarin programmes. In addition, Blend anticipates developing Pentarins in partnership with biotechnology and pharmaceutical collaborators who have their own proprietary targeting protein scaffolds which can be deployed to create novel biologic drug conjugates using Blend’s Pentarin platform.
Related News
-
News CPHI Podcast Series: the power of digital marketing in pharma
Digital marketing is a valuable tool for many industries, and the pharmaceutical and healthcare industry is no exception. The CPHI Podcast Series covers how marketing can be used by companies to increase their engagement and overcome challenges.&n... -
News Novel approach to creating sustainable packaging from rice husks
Researchers have created a new approach to the designing of eco-friendly nanofibres extracted from rice husks, addressing the critical need for sustainable packaging materials in food and biopharmaceutical products. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond
The next episode of the CPHI Podcast Series delves into the science and background behind some recent developments in the field of Alzheimer's disease and neurological disorders. -
News Is patient centricity the future of pharmaceutical manufacturing?
In this interview with Sandra Sánchez y Oldenhage, President of PharmAdvice, she speaks to the importance of considering patients in the manufacturing stages of the pharmaceutical supply chain, and how it can redefine healthcare. -
News CPHI Podcast Series: How to leverage AI for Drug Discovery
Artificial intelligence is the topic of debate in the latest episode from the CPHI Podcast Series, where Digital Editor Lucy Chard speaks with Bill Whitford of DPS Group about the integration of AI in healthcare.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance